Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Repligen Corp RGEN

Technology Scientific & Technical Instruments
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial... see more

Recent & Breaking News (NDAQ:RGEN)

Repligen to Present at the 2013 Stephens Fall Investment Conference

Globe Newswire November 6, 2013

Repligen Completes Expansion of U.S. Manufacturing Facility

Globe Newswire November 1, 2013

Repligen to Report Third Quarter 2013 Financial Results

Globe Newswire October 24, 2013

Repligen to Present at the Stifel Healthcare Conference 2013

Globe Newswire September 4, 2013

Repligen Receives First Milestone Payment From Pfizer Under Licensing Agreement for Spinal Muscular Atrophy Program

Globe Newswire September 4, 2013

Repligen Reports Second Quarter 2013 Financial Results

Globe Newswire August 1, 2013

Repligen to Report Second Quarter 2013 Financial Results

Globe Newswire July 18, 2013

Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference

Globe Newswire May 23, 2013

Repligen Reports First Quarter 2013 Financial Results

Globe Newswire May 2, 2013

Repligen to Report First Quarter 2013 Financial Results

Globe Newswire April 23, 2013

Free Research Reports on BYD, NLY, RGEN and VLO Issued by the Bedford Report

Marketwired April 8, 2013

InvestorsGuru.com 40 Filtered Mid-Day Market Movers Recap

Investors Guru April 7, 2013

Repligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 2013

Troy Schwensen March 7, 2013

Repligen to Report Fourth Quarter and Full Year 2012 Financial Results

Troy Schwensen March 1, 2013

Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program

Business Wire January 3, 2013